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Background: The IMP3 is an oncofetal protein, which has been recently proposed as a diagnostic and prognostic marker in many cancers, 
including colorectal adenocarcinoma. The overexpression of IMP3 seems to have a correlation with patient’s prognosis.
Objectives: In this study, the relationship between IMP3 expression in colorectal adenocarcinoma and clinicopathologic findings was 
assessed.
Patients and Methods: In this study 112 colorectal tumor paraffin blocks of Rasoul-e-Akram hospital were stained for IMP3 and slides 
were assessed for intensity and extent of positivity. The statistical relationships between marker expression and clinicopathologic findings 
(degree of differentiation, tumor size, depth of invasion and lymph nodes metastasis) were assessed. Data were analyzed by the SPSS 21 
software and logistic regression and chi-square test, with p-values of less than 0.05 indicating statistical significance.
Results: Immunoreactivity pattern of IMP3 was cytoplasmic in different clinicopathologic findings. Among different clinicopathologic 
findings, we found a statistical relationship between tumor differentiation and IMP3 (P = 0.047); so that, the poorly differentiated tumors 
were positive for this marker. No relationship was found between tumor size, depth of invasion or lymph node involvement and IMP3.
Conclusions: IMP3 immunoreactivity was associated with poor differentiation of tumor yet not associated with tumor size depth of 
invasion or lymph node involvement.
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1. Background
Country reports of cancer registration by the cancer or-
ganization of the Iranian ministry of health, treatment 
and medical training in 2007 indicated that colorectal 
cancer in males and females with the age standardized 
rate (ASR) of 8.85 and 9.63 was ranked as the third and 
fifth most common tumor in Iran, respectively. Generally, 
colorectal cancer with 4493 and 4887 registered cases in 
years 2006 and 2007 was the forth most common tumor 
in Iran. According to this report 2127 females and 2679 
males were diagnosed with colorectal adenocarcinoma 
in 2007. However, colorectal cancer is the most curable 
tumor of the gastrointestinal tract and most of its mor-
talities are preventable. Recently, IMP3 aside other on-
cofetal proteins has been suggested as an effective bio-
marker in pathogenesis and invasion of many epithelial 
cell cancers. This marker plays an important role in sta-
bility and trafficking of mRNA, cell growth, proliferation 
and migration in embryogenesis and tumoral cells, and 
is expressed in evolved epithelia, muscle and placenta 
yet is not detectable in adult tissues (1, 2). Furthermore, 
IMP3 or insulin like growth factor 2 mRNA binding pro-
tein 3 (IGF2BP3) is an RNA-binding oncofetal protein, 
which weighs 65 - 70 KD and includes 580 amino acid and 
four K-homolog domains and is coded by the IMP3 gene 
on chromosome  7p11.5 and produces a 4350 base-pair 
mRNA (1, 3). Overexpression of IMP3 (also known as L523S) 
has been reported in many cancers such as pancreatic 
carcinoma (4, 5), lung adenocarcinoma (6-8), renal cell 
carcinoma (9-11), hepatocellular carcinoma, malignant 
melanoma (12), gastric cancer (13), ovarian carcinoma (14, 
15), urothelial carcinoma of bladder (16), cervical carci-
noma (17, 18), and testis cancer (19). It has been suggested 
as a prognostic marker in some cancers including breast 
cancer (20), neuroblastoma (21), and cervical cancer (18). 
Determination of the correlation between this tumoral 
biomarker and clinicopathologic findings will reveal its 
role in pathogenesis, development and metastasis of tu-
mors, and recognition of high-risk patients, allows their 
treatment by severe regimes and detailed follow-ups 
with short intervals, reducing their mortality. Also, this 
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biomarker can be used as a potential pharmacologic tar-
get in patient’s treatment.
2. Objectives
With respect to the inconsistent results of previous 
studies in this field and the importance of colorectal car-
cinoma and its mortality rate in Iran, this study aimed to 
determine IMP3 expression in 112 colorectal cancers by 
immunohistochemistry assessment, and investigate its 
correlation with clinicopathologic findings.
3. Patients and Methods
Patients with diagnosis of colorectal cancer, who were 
treated with surgical resection at Rasoul-e-Akram hospi-
tal, from year 2010 to 2012, were recruited in this study. 
We used a computer database for collecting clinicopath-
ologic features and omitted the cases with neoadjuvant 
chemoradiotherapy to minimize treatment-induced 
bias. The cases with a diagnosis of non-epithelial, muci-
nous or signet ring cancers were also excluded for ho-
mogenization of the selected cases. Finally, a total num-
ber of 112 patients with colorectal adenocarcinoma (not 
otherwise specified (NOS) type) were included in the im-
munohistochemistry (IHC) study. There were informed 
consents for medical research from all patients in the 
documented files.
3.1. Histological Evaluation
The hematoxylin and eosin stained slides of the selected 
cases were re-examined by a pathologist and new slides 
were prepared from paraffin blocks when needed. He 
categorized tumors as well-to-moderate or poorly differ-
entiated adenocarcinoma. The invasion of tumor cell to 
different layers of colon wall (pT) was recorded by the pa-
thologist. Tumor sizes were extracted from the computer 
database with one missing data. None of the cases were 
categorized in the PT1 category.
3.2. Immunohistochemical Evaluation
During the re-examination of H& E slides, an area with 
an extent of about 1 cm2 was marked from invasive front 
of tumor. Tissue sections (five micrometers) were pre-
pared from the marked areas. For antigen retrieval, de-
paraffinized tissue sections were rehydrated in sodium 
citrate buffer (pH 6) and microwaved in a pressure cook-
er for 10 minutes. Then, the slides were incubated for 15 
minutes with peroxidase blocking reagent (Dako). Once 
again slides were incubated overnight in a wet cham-
ber with a mouse monoclonal antibody against IGF2BP3 
(IMP3; clone 69.1; Dako) at a dilution of 1:100. Negative 
tissue controls were covered by phosphate-buffered 
saline (PBS). For visualization, Envision Horseradish 
peroxidase (HRP) (Dako), diaminobenzidine (Dako), 
counterstaining by hematoxylin and finally mounting 
were respectively applied to the slides. Human placenta 
was used as a positive control in each work run. The IHC 
slides were completely examined for IMP3 immunoreac-
tivity by microscopy and were scored for the extent of 
immunoreactivity as zero (0%), one (1% - 25%), two (26% 
- 50%), three (51% - 75%), and four (76% - 100%), depending 
on the percentage of positive tumoral cells. Staining in-
tensity for Imp3 was scored as zero (negative staining), 
one (weak staining), two (moderate staining), and three 
(strong staining). The sums of staining extent and inten-
sity were utilized for making the final scores. Based on 
the overall scores, IHC slides were categorized into two 
groups: zero to four (negative staining) and five to eight 
(positive staining).
3.3. Statistical Analysis
Statistical analysis including logistic regression and chi-
square were carried out using the SPSS software version 
21. All P values were two-tailed and considered statistically 
significant when less than 0.05. The hypothesis was that 
IMP3 immunoreactivity was associated with tumor differ-
entiation, size, and depth of invasion or lymph nodes in-
volvement. There was only a single data missing for tumor 
size, which was confirmed to have not affected the results.
4. Results
Among the database of 112 colorectal cases at Rasoul-
e-Akram hospital recruited to our prospective cohort 
study, 56 (50%) cases showed positive immunoreactivity 
for IMP3 with the IHC staining method. Figure 1 shows 
the immunoreactivity of IMP3 in different normal and 
tumoral colonic tissues. In our study the pattern of stain-
ing for IMP3 in positive tumoral cells was cytoplasmic. 
All adjacent colonic mucosa present in the slides were 
negative or weakly positive. Interestingly, lymphocytes of 
germinal centers in mucosa-associated lymphoid tissues 
were IMP3 positive, acting as a positive internal control 
in some cases in our IHC study. Table 1 demonstrates the 
clinicopathologic characteristics of the 112 colorectal pa-
tients treated by surgical resection. The mean of tumor 
maximum diameter was 5.2 cm with standard deviation 
(SD) of 2.3 cm. Most of the patients (89 cases) were cate-
gorized in the pT3 group with no pT1 category (Table 2). 
Sixty-one (54.5%) patients had regional lymph nodes me-
tastasis. There were only 10 high-grade (poorly differenti-
ated) colorectal tumors and most of the cases (91%) were 
categorized in the low-grade group.
As it is shown, only poorly differentiation of colorectal 
tumor is borderline associated with IMP3 positivity (P 
= 0.047). We did not find any significant association be-
tween IMP3 immunoreactivity and other clinicopatho-
logic features including tumor size, depth of invasion 
(pT) or lymph node metastasis (pN).
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Figure 1. Immunohistochemistry Staining for IMP3
A, human placenta as positive control; the pattern of staining was cytoplasmic. B, well differentiated colorectal adenocarcinoma (left side) aside normal 
colonic mucosa (right side), which was IMP3 negative. C, lymphocytes of germinal center of mucosa associated lymphoid tissue (upper left) were positive 
for IMP3; the infiltrative tumoral cells were IMP3 negative in this case. D, IMP3 positive tumoral cells in a high-grade colorectal adenocarcinoma.
Table 1.  Association of IMP3 Immunoreactivity With the Assessed Clinicopathologic Features a
Clinicopathologic Findings Patients
All cases 112 (100)
Tumor diameter, cm 5.2 ± 2.3









Well to moderate differentiation, low grade 102 (91.1)
Poor differentiation, high grade 10 (8.9)
a  Data are presented as No. (%) or mean ± SD.
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Table 2.  Correlation of IMP3 Expression and Clinicopathologic Features in 112 Colorectal Adenocarcinoma Cases a
Characteristics IMP3 Positive IMP3 Negative P Value
Tumor size, cm 0.08
> 5 28 (25.2) 30 (27)
< 5 27 (24.3) 26 (23.4)
Tumor depth of invasion, pT 0.07 b
T1 0 (0) 0 (0)
T2 6 (5.3) 8 (7.1)
T3 46 (41.07) 43 (38.39)
T4 4 (3.5) 5 (4.49)
Lymph nodes metastasis, pN 0.8 c
Node negative 31 (27.6) 30 (26.7)
Node positive 25 (22.4) 26 (23.4)
Tumor differentiation 0.047
Well to moderate differentiation, low grade 48 (42.8) 54 (48.2)
Poor differentiation, high grade 8 (7.1) 2 (1.7)
a  Data are presented as No. (%).
b  T1+T2 vs. T3+T4.
c  N negative vs. N positive.
5. Discussion
It has been reported that IGF2BP3 is a prognostic and 
diagnostic biomarker in many tumoral tissues includ-
ing colorectal adenocarcinoma (22-25). We stained 112 
formalin fixed paraffin embedded colorectal tumor 
tissues (NOS type) with an immunohistochemistry 
method and showed that 50% of these tumors were cy-
toplasmically positive for IMP3. We found an association 
between IGF2BP3 positivity and high-grade tumors. It 
was implied that IMP3 expression could mark a group 
of colorectal tumors with potential aggressive behavior. 
In the present study, similar to previous researches, we 
found no immunoreactivity in normal colon tissues, 
which could be used for diagnosis of colonic mass bi-
opsy. As indicated by the study of Lochhead et al. (22), 
we also showed that lymphocytes of germinal centers in 
mucosa-associated lymphoid tissues were always posi-
tive for IMP3 as an oncofetal cytoplasmic protein, which 
can be troublesome for the diagnosis of crushed tumor 
tissue biopsy. Also, our results showed a relationship be-
tween the grade of the tumor differentiation and IMP3 
immunoreactivity, while this relationship was not found 
by the studies of Lin et al. (23), Li et al. (24) and Yuan et 
al. (25). Consistent with the study of Lochhead et al. (22) 
and Lin et al. (23) and in contrast with the research of 
Yuan et al. (25), there was no relationship between tu-
mor size and the grade of tumor differentiation in the 
present study. In contrast with the study of Lochhead 
et al. (22) and Lin et al. (23) an insignificant correlation 
between the depth of tumor and lymph node involve-
ment was found. Table 3 compares our results with a few 
previous important researches. As it can be seen, all of 
these previous studies used tissue microarray for the 
IHC study that shows only a small area of tumors. This 
difference could be due to the removal of mucinous and 
signet-ring cell colorectal tumors in our study and the 
evaluation of the depth of the tumor rather than the tu-
mor stage in our study. Another possible reason for this 
difference is the limited number of samples in the pres-
ent study. In conclusion, the present study showed that 
IMP3 immunoreactivity was associated with poor differ-
entiation of tumors, yet not associated with tumor size 
depth of invasion or lymph node involvement.
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Table 3.  Comparison of the Results of the Present Study With a Few Previous Important Researches a






Present study 112 IHC No No Yes No
Lin et al. (23) 186 TMA No Yes No Yes
Lochhead et al. (22) 671 TMA No Yes Yes Yes
Li et al. (24) 203 TMA No Yes No Yes
Yuan et al. (25) 186 TMA Yes Yes No Yes
a  Abbreviations: IHC, immunohistochemistry; and TMA, tissue microarray.
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